VERGANI, BARBARA
VERGANI, BARBARA
Universita' degli Studi di MILANO
Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment
2017-01-01 M. Tazzari, V. Indio, B. Vergani, L. De Cecco, F. Rini, T. Negri, C. Camisaschi, M. Fiore, S. Stacchiotti, G.P. Dagrada, P.G. Casali, A. Gronchi, A. Astolfi, M.A. Pantaleo, A. Villa, C. Lombardo, F. Arienti, S. Pilotti, L. Rivoltini, C. Castelli
Automatic quantification of histochemical images of cancerous tissue samples: a method based on a computational model of human color vision
2019-07-26 E. Casiraghi, B. Vergani, B. Barricelli, S. Liberini, B.E. Leone, A. Rizzi
Evidence for a role of autoinflammation in early-phase psoriasis
2019-12-01 D. Fanoni, L. Venegoni, B. Vergani, S. Tavecchio, A. Cattaneo, B.E. Leone, E. Berti, A.V. Marzano
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir
2008-01-01 B. Vergani, M. Lo Cicero, O. Viganò, F. Sirianni, S. Ferramosca, P. Vitiello, P. Di Vincenzo, M.P. De Pasquale, M. Galli, S. Rusconi
Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
2014-11-02 A. Giacomelli, L. Oreni, M. Franzetti, V. Di Cristo, B. Vergani, M. Morosi, E. Colella, M. Galli, S. Rusconi
Ki67 nuclei detection and ki67-index estimation : a novel automatic approach based on human vision modeling
2019-12-30 B.R. Barricelli, E. Casiraghi, J. Gliozzo, V. Huber, B.E. Leone, A. Rizzi, B. Vergani
Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy
2015-08-22 D. Miglietta, C. De Palma, C. Sciorati, B. Vergani, V. Pisa, A. Villa, E. Ongini, E. Clementi
pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma
2018-01-01 O. Kuchuk, A. Tuccitto, D. Citterio, V. Huber, C. Camisaschi, M. Milione, B. Vergani, A. Villa, M. Alison, S. Carradori, C. Supuran, L. Rivoltini, C. Castelli, V. Mazzaferro
Predictive factors of therapeutic success of a HAART regimen including atazanavir with or without ritonavir in HIV-infected patients
2012-11-11 A. Giacomelli, M. Franzetti, B. Vergani, L. Oreni, M. Morosi, V. Di Cristo, E. Colella, O. Viganò, M. Galli, S. Rusconi
Tipranavir in the Protease Inhibitors Arena
2011-12-01 B. Vergani, S. Rusconi
Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30+ T lymphocytes with progression
2014-01-01 V. Vallacchi, E. Vergani, C. Camisaschi, P. Deho, A.D. Cabras, M. Sensi, L. De Cecco, N. Bassani, F. Ambrogi, A. Carbone, F. Crippa, B. Vergani, P. Frati, F. Arienti, R. Patuzzo, A. Villa, E. Biganzoli, S. Canevari, M. Santinami, C. Castelli, L. Rivoltini, M. Rodolfo
Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-Institution retrospective study before and after the introduction of HAART
2013-01-01 M. Franzetti, F. Adorni, C. Parravicini, B. Vergani, S. Antinori, L. Milazzo, M. Galli, A.L. Ridolfo